About the initiative “Saving the hearts of Ukraine”
The government is developing a network to help patients with acute myocardial infarction. This will allow co-financing to purchase the angiographic equipment necessary for stenting and to ensure free emergency stenting in patients with acute myocardial infarction.
Today, according to the calculations of the Association of Interventional Cardiologists of Ukraine, the estimated need for Ukraine for emergency stenting in patients with acute myocardial infarction is 25,000, whereas in 2016 only 6,800 were spent.
Thanks to the implementation by the international organization of centralized procurement of stent systems and consumables, for the first time in the history of our state, every patient who needs emergency angiography / stenting can receive it for FREE.
The government adopted a resolution of the Cabinet of Ministers of Ukraine "On approval of the procedure and conditions for granting a subvention from the state budget to local budgets for the purchase of angiographic equipment." It provides for the purchase of stationary angiographic equipment on co-financing from local budgets.
Reperfusion centers should operate 24 hours 7 days a week, 365 days a year (24/7/365). Each patient who requires urgent stenting will be provided with high-quality and timely diagnosis and effective and free treatment. According to European treatment protocols, stenting should be carried out in the first 2:00 of the patient’s contact with the medical staff (maximum 12:00 from the onset of symptoms).
Full information about the initiative "Save the hearts of Ukraine" can be found at: http://moz.gov.ua/kardiocentri
Disease prevention is the most reasonable treatment. INTERCHEM company has released a new drug, “Rosuvastatin ІC”, which is used for hypercholesterolemia and for the prevention of cardiovascular disorders.
Proven efficacy of rosuvastatin in the treatment of adults with hypercholesterolemia, regardless of race, gender, or age, as well as patients of special groups, such as diabetic patients or patients with familial hypercholesterolemia. It has been reported that approximately 80% of patients with type IIa and IIb hypercholesterolemia who took rosuvastatin at a dose of 10 mg managed to achieve standard target levels of LDL cholesterol established by the European Society of Atherosclerosis (EAS; 1998) (
Patients aged 45-70 years with a low risk of coronary heart disease, who used rosuvastatin at a dose of 40 mg 1 time per day for 2 years, showed a significant slowdown in the progression of maximal TCAMA at 12 points of the carotid artery compared to placebo.
"Rosuvastatin ІC" prescription in the form of tablets of 5, 10, 20 and 40 mg.